Treatment > Cloretazine


Brain Tumors


Bai F, Minkin P, Fraga CH, O'shaughnessy MA, Gururangan S, Stewart CF. 
Determination of Cloretazine [trade mark (VNP40101M)] and its active metabolite (VNP4090CE) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS).
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Mar 24; [Epub ahead of print]
PMID: 17446145 [PubMed - as supplied by publisher]

Gururangan S, Turner CD, Stewart CF, O'Shaughnessy M, Kocak M, Poussaint TY, Phillips PC, Goldman S, Packer R, Pollack IF, Blaney SM, Karsten V, Gerson SL, Boyett JM, Friedman HS, Kun LE
Phase I Trial of VNP40101M (Cloretazine) in Children with Recurrent Brain Tumors: A Pediatric Brain Tumor Consortium Study
Clin Cancer Res. 2008 Feb 15;14(4):1124-30
 Abstract |
DBLinks | BL 7:6

 

HOME | Detection | Diagnosis | Epidemiology | Etiology & Pathogenesis | Integrative Medicine | Overall Mngt & Case Reports | Prevention | Prognosis | Psychosocial Aspects | Treatment 
About BrainLife
|
Children's Corner | E-mail Alerts | Journals | Newsletter | Patients & Caregivers | Search | Stem Cells | WHO Classification | SITEMAP